Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01659814 · ClinicalTrials.gov registry record

Dopamine Neurotransmission in Major Depression

A clinical trial of Major Depressive Disorder and Anhedonia, sponsored by Mclean Hospital.

Completed
Registry status
71
Enrollment target
2
Study locations

NCT01659814: Completed study of Major Depressive Disorder and Anhedonia, sponsored by Mclean Hospital.

NCT01659814 is a study of Major Depressive Disorder and Anhedonia that has completed, run by Mclean Hospital. The registered enrollment target is 71 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01659814, a study of Major Depressive Disorder and Anhedonia, has completed, sponsored by Mclean Hospital.

COMPLETED
Registry status
71 participants
Enrollment target
2
Study locations

Study Summary

The overall aim of this study is to utilize an integrative research model in order to dynamically assess reward-related dopamine (DA) transmission in major depressive disorder (MDD) and test the role of dysfunctional DA release in depression and anhedonia. The first arm of this line of research (PET scan) aims to investigate phasic DA release in MDD during incentive motivation. The investigators will utilize an established molecular imaging technique to measure striatal DA release dynamically during performance of testing and control versions of a monetary incentive delay task, which involves anticipation and receipt of monetary rewards. In doing so, this experiment will link together independent lines of research that have associated depression with decreased hedonic responsiveness, impaired reinforcement learning and dysfunctional DA transmission. We hypothesize that, relative to matched controls, unmedicated MDD subjects will show reduced reward-related ligand (11C-raclopride) displacement. Reduced ligand displacement will be interpreted as indicating reduced task-induced release of endogenous striatal DA in response to reward-predicting cues and unpredictable reward in MDD subjects. In the second arm of this research (EEG recording), the investigators aim to probe the spatio-temporal dynamics of brain mechanisms underlying positive and negative reinforcement learning in MDD and their relations to phasic DA. Participants will perform the probabilistic stimulus selection task (PSST) while event-related potentials (ERPs) are collected. The investigators expect that, relative to matched controls, unmedicated MDD subjects will show reduced positive reinforcement learning, potentiated negative reinforcement learning, and larger (i.e., more negative) feedback-related negativity (FRN) in response to positive reinforcement (indicative of reduced DA transmission). Moreover, the investigators hypothesize that a more negative FRN in response to positive reinforcement will

Primary Outcome

ERPs will be generated during performance of the probabilistic stimulus selection task (PSST). Feedback-locked ERPs will be computed within epochs starting 100 ms before the feedback and lasting 924 ms. ERPs will be baseline-corrected to the first 100 ms of the extracted epoch. The feedback-related negativity (FRN) will be defined as the most negative peak 200-400 ms at frontocentral electrodes (Fz, FCz, Cz) after positive or negative feedback. Group (MDD vs. controls) x Trial Type (accuracy on

Study Locations (2)

Massachusetts

  • McLean Hospital - Belmont
  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2011-03
Est. Completion 2012-12
Mclean Hospital

140 total trials

What the finished NCT01659814 record still lists

NCT01659814 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (81% lower).

The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT01659814 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01659814 about?

NCT01659814 is a clinical study titled "Dopamine Neurotransmission in Major Depression". The overall aim of this study is to utilize an integrative research model in order to dynamically assess reward-related dopamine (DA) transmission in major depressive disorder (MDD) and test the role of dysfunctional DA release in depression and anhedonia. The first arm of this line of research (PE...

What is the current status of trial NCT01659814?

This trial is currently completed. The enrollment target is 71 participants. The study started on 2011-03. Estimated completion is 2012-12.

What conditions does trial NCT01659814 study?

This clinical trial studies the following conditions: Major Depressive Disorder, Anhedonia.

Who is sponsoring clinical trial NCT01659814?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01659814 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01659814's enrollment target sits among peer trials

71 155th of 282 higher than 127 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05452889 · 71 participants · Early Phase 1

    PET Image in PAH Patients

  • NCT05766943 · 71 participants · NA

    Reduction of Myopotential Interference With Smart Pass in S-ICD Patients

  • NCT06229678 · 71 participants · Early Phase 1

    Ketones, SGLT2, HFrEF

  • NCT06377566 · 71 participants · Phase 2

    A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01659814, the US trial registry maintained by the National Library of Medicine. NCT01659814 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.